SCHEMBL29626014

SCHEMBL29626014

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccccc3-n3c4ccc(N(c5ccccc5)c5ccccc5)cc4c4cc(N(c5ccccc5)c5ccccc5)ccc43)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.34
ADORA3 P0DMS8 1/20 0.34
ALOX15 P16050 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
PDE5A O76074 2/20 0.33
ALDH1A1 P00352 3/20 0.33
MAPT P10636 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
KDM4E B2RXH2 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 2/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17897522 0.96 ALDH1A1 (0.33) TSHRADORA3ALOX15ADORA2AADORA2B
SCHEMBL20110547 0.96 ALDH1A1 (0.33) TSHRADORA3ALOX15ADORA2AADORA2B
SCHEMBL19626567 0.94 ALDH1A1 (0.35) TSHRADORA3ALOX15ADORA2AADORA2B
SCHEMBL27109946 0.91 RAC2 (0.35) PDE5AALDH1A1L3MBTL1KDM4E
SCHEMBL20110496 0.91 RAC2 (0.35) PDE5AALDH1A1L3MBTL1KDM4E
SCHEMBL17897553 0.88 MEN1 (0.33) TSHRADORA2AADORA1ALDH1A1MAPT
SCHEMBL18511462 0.87 MEN1 (0.37) TSHRADORA2AADORA1ALDH1A1MAPT
SCHEMBL20110468 0.87 CYP2D6 (0.41) TSHRALOX15PDE5AALDH1A1MAPT
SCHEMBL17400232 0.87 L3MBTL1 (0.34) TSHRPDE5AMAPTL3MBTL1LMNA
SCHEMBL17897556 0.86 MEN1 (0.35) TSHRADORA2AADORA1PDE5AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250344566-A1 ORGANIC ELECTROLUMINESCENT ELEMENT TOSOH CORPORATION (JP) 2025-11-06 US disclosed
CN-120058670-A Cyclic azine compound, material for organic electroluminescent element, electron transport material for organic electroluminescent element, and organic electroluminescent element 东曹株式会社 2025-05-30 CN disclosed
CN-114096528-B Cyclic azine compound, material for organic electroluminescent element, electron transport material for organic electroluminescent element, and organic electroluminescent element 东曹株式会社 2025-03-21 CN disclosed
CN-119318234-A Organic electroluminescent element 东曹株式会社 2025-01-14 CN disclosed
WO-2024005118-A1 ORGANIC ELECTROLUMINESCENT ELEMENT 東ソー株式会社 2024-01-04 WO disclosed
US-20220274952-A1 CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, ELECTRON TRANSPORT MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, AND ORGANIC LIGHT EMITTING DIODE TOSOH CORPORATION (JP) 2022-09-01 US disclosed
EP-4006023-A1 CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRON TRANSPORT MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, AND ORGANIC ELECTROLUMINESCENT ELEMENT Tosoh Corporation (JP) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274952-A1 CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, ELECTRON TRANSPORT MATERIAL FOR ORGANIC LIGHT EMITTING DIODE, AND ORGANIC LIGHT EMITTING DIODE AZI2, OXA1L, TMEM109 TSHR 3330/4885ADORA3 668/4885ALOX15 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.